These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28521651)

  • 1. Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study.
    Hsu F; Nichol A; Toriumi T; De Caluwe A
    Acta Oncol; 2017 Sep; 56(9):1175-1180. PubMed ID: 28521651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutation status on brain metastases from non-small cell lung cancer.
    Hsu F; De Caluwe A; Anderson D; Nichol A; Toriumi T; Ho C
    Lung Cancer; 2016 Jun; 96():101-7. PubMed ID: 27133758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.
    Sekine A; Kato T; Hagiwara E; Shinohara T; Komagata T; Iwasawa T; Satoh H; Tamura K; Kasamatsu T; Hayashihara K; Saito T; Takahashi H; Ogura T
    Lung Cancer; 2012 Jul; 77(1):64-9. PubMed ID: 22335887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC.
    Wang BX; Ou W; Mao XY; Liu Z; Wu HQ; Wang SY
    Clin Neurol Neurosurg; 2017 Sep; 160():96-100. PubMed ID: 28704781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.
    Ge M; Zhuang Y; Zhou X; Huang R; Liang X; Zhan Q
    J Neurooncol; 2017 Nov; 135(2):413-418. PubMed ID: 28780743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
    Okuma Y; Kashima J; Watanabe K; Homma S
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1601-1611. PubMed ID: 29858682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
    J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
    Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
    J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
    Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
    AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
    Castañón E; Rolfo C; Viñal D; López I; Fusco JP; Santisteban M; Martin P; Zubiri L; Echeveste JI; Gil-Bazo I
    J Transl Med; 2015 Aug; 13():257. PubMed ID: 26248464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan.
    Guan J; Chen M; Xiao N; Li L; Zhang Y; Li Q; Yang M; Liu L; Chen L
    Med Oncol; 2016 Jan; 33(1):1. PubMed ID: 26589606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
    Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
    Hendriks LE; Smit EF; Vosse BA; Mellema WW; Heideman DA; Bootsma GP; Westenend M; Pitz C; de Vries GJ; Houben R; Grünberg K; Bendek M; Speel EJ; Dingemans AM
    Lung Cancer; 2014 Apr; 84(1):86-91. PubMed ID: 24529684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
    Song Z; Zhang Y
    J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer.
    Yuan R; Yamada A; Weber B; Ho C
    J Neurooncol; 2016 May; 127(3):525-33. PubMed ID: 26780337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
    Shin SM; Cooper BT; Chachoua A; Butler J; Donahue B; Silverman JS; Kondziolka D
    J Neurooncol; 2016 Feb; 126(3):483-91. PubMed ID: 26520640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
    Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
    Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.